var title_f28_23_29040="Corneal light reflex";
var content_f28_23_29040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal light reflex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The corneal light reflex test involves shining a light onto the child's eyes from a distance and observing the reflection of the light on the cornea with respect to the pupil. The location of the reflection from both eyes should appear symmetric and generally slightly nasal to the center of the pupil. A) Normal corneal reflex. B) Corneal light reflex in esotropia. C) Corneal light reflex in exotropia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29040=[""].join("\n");
var outline_f28_23_29040=null;
var title_f28_23_29041="Clofazimine: International drug information";
var content_f28_23_29041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clofazimine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10830630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Clofozine (IN);",
"     </li>",
"     <li>",
"      Hansepran (IN);",
"     </li>",
"     <li>",
"      Lamcoin (TH);",
"     </li>",
"     <li>",
"      Lampren (JP, NL, ES);",
"     </li>",
"     <li>",
"      Lamprene (AU, CH, CZ, FR, GR, HK, IR, MY, NZ, SA, UK);",
"     </li>",
"     <li>",
"      MB-Combi (SA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F10830631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      B-663;",
"     </li>",
"     <li>",
"      Clofazimina;",
"     </li>",
"     <li>",
"      Clofazimine;",
"     </li>",
"     <li>",
"      Clofaziminum;",
"     </li>",
"     <li>",
"      G-30320;",
"     </li>",
"     <li>",
"      Klofatsimiini;",
"     </li>",
"     <li>",
"      Klofatzimin;",
"     </li>",
"     <li>",
"      Klofaziminos;",
"     </li>",
"     <li>",
"      NSC-14106",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10830632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F10830633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Labeled: Hansen's Disease (leprosy): Treatment of severe erythema nodosum leprosum (ENL) reactions in multibacillary (MB) leprosy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Off-label/Investigational: Rarely used as treatment of multidrug resistant tuberculosis (MDR-TB) and in",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex (MAC) complex infections in patients with acquired immune deficiency symptoms (AIDS)",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F10830635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Leprosy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: 2 mg/kg every other day (in combination with dapsone and rifampin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 50 mg/day (in combination with dapsone and rifampin) for 24 months",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     International: No longer available commercially. In nations where a national leprosy elimination program exists, the Ministries of Health make an official request to the World Health Organization (WHO) for clofazimine. In nations where no such program exists, doctors or pharmacists from individual institutions contact the WHO with a request. A request can be made to the WHO via a letter, fax, or email to verify that the drug will be used to treat a severe ENL reaction due to leprosy and how many patients need the drug. If these conditions are met, a free supply of clofazimine will then be made available. For treatment of MDR-TB, the WHO handles decisions regarding distribution on an individual case-by-case basis. For additional information: file://www.who.int/lep/mdt/clofazimine/en/.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     United States: Clofazimine is distributed through the National Hansen&rsquo;s Disease Program (NHDP). NHDP holds the Investigational New Drug (IND) clofazimine for treatment in the United States. In order for physicians to obtain clofazimine, they will have to register as an investigator under the NHDP IND. This will require submitting a curriculum vitae and a signed FDA form 1572 to the NHDP. For further information, or to request investigator status, please call the NHDP at 1-800-642-2477. For additional information: file://www.hrsa.gov/hansens/clinical/regimens.htm.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10830636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, oral: 50 mg, 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15931 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29041=[""].join("\n");
var outline_f28_23_29041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10830630\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10830631\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10830632\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10830633\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10830635\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821256\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10830636\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/15931\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/15931|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_23_29042="Sodium hypochlorite solution: Drug information";
var content_f28_23_29042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium hypochlorite solution: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/20/30019?source=see_link\">",
"    see \"Sodium hypochlorite solution: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atrapro&trade; Dermal;",
"     </li>",
"     <li>",
"      Dakin's Solution;",
"     </li>",
"     <li>",
"      Di-Dak-Sol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Disinfectant, Antibacterial, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Disinfectant:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atrapro&trade; Dermal spray: Topical: Apply to affected area 3 times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dakin&rsquo;s solution, Di-Dak-Sol:  Topical via irrigation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lightly-to-moderately exudative wounds: Apply once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Highly exudative or contaminated wounds: Apply twice daily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dakin's Solution: 0.125% (473 mL); 0.25% (473 mL); 0.5% (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Di-Dak-Sol: 0.0125% (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atrapro&trade; Dermal: 0.004% (236 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; do",
"     <b>",
"      not",
"     </b>",
"     ingest. Protect intact skin with a moisture barrier ointment or skin sealant as needed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atrapro&trade; Dermal (0.004%): Management (via debridement) of wounds such as stage I-IV pressure ulcers; partial and full thickness wounds; diabetic foot ulcers; post surgical and donor sites; first- and second-degree burns",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dakin&rsquo;s Solution (0.125%, 0.25%, 0.5%); Di-Dak-Sol (0.0125%): Prevention/treatment of skin and tissue infections, cuts, abrasions, skin ulcers; pre- and postsurgery",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F12769484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       A potential for confusion associated with labeling of strengths for Dakin&rsquo;s solution manufactured by Century Pharmaceuticals exists. The labels list strengths as full strength at 0.5%, half strength at 0.25%, and quarter strength at 0.125%. This terminology is confusing to healthcare providers who consider half strength and quarter strength to correspond to 0.5% and 0.25%, respectively. Of note, most hospitals use a modified Dakin&rsquo;s solution of 0.025% for wound care; studies have suggested that concentrations of Dakin&rsquo;s solution &gt;0.025% may potentially be harmful for wound healing.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Irritating to skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Dissolves blood clots, delays clotting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid eye or mucous membrane contact.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Di-Dak-Sol External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.0125% (473 mL): $9.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (H-Chlor 12 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.125% (473 mL): $10.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HySept External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (473 mL): $10.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (473 mL): $10.85",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9933 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-109.224.62.197-8A62FE5C28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29042=[""].join("\n");
var outline_f28_23_29042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221802\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221814\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221803\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221810\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221804\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221794\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221783\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221796\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221795\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12769484\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221812\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221798\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221786\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300057\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222996\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323869\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9933\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9933|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/20/30019?source=related_link\">",
"      Sodium hypochlorite solution: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_23_29043="NB head position resuscitate";
var content_f28_23_29043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Head position for neonatal resuscitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 690px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top panel demonstrates the correct head position with the baby positioned on the back with the neck slightly extended resulting in alignment of the posterior pharynx, larynx, and trachea, which allows unrestricted air entry.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29043=[""].join("\n");
var outline_f28_23_29043=null;
var title_f28_23_29044="Pediatric airway anatomy PI";
var content_f28_23_29044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Lungs in a healthy child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 521px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is what the lungs of a healthy child look like. They sit on the left and right sides of the upper chest, inside the ribcage. When a child takes a breath, air comes in through the nose and mouth, goes down the throat, and into the main airway leading to the lungs called the \"trachea\". The trachea branches into the left and right bronchus, which carry air to each lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29044=[""].join("\n");
var outline_f28_23_29044=null;
var title_f28_23_29045="Surgical anatomy of the parathyroid glands";
var content_f28_23_29045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical anatomy of the parathyroid glands",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/23/29045/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/23/29045/contributors\">",
"     Melanie L Richards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/23/29045/contributors\">",
"     Tracy S Wang, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/23/29045/contributors\">",
"     Julie Ann Sosa, MD, MA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/23/29045/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/23/29045/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/23/29045/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/23/29045/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/23/29045/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parathyroid glands were first identified by Sir Richard Owen in the Great Indian Rhinoceros in 1850 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/1\">",
"     1",
"    </a>",
"    ]. They were identified in humans by Ivar Sandstrom, a Swedish medical student, in 1880 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/2\">",
"     2",
"    </a>",
"    ]. The first parathyroidectomy was reported by Felix Mandl in 1929, 30 years prior to the isolation of human parathyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success of the surgical management of parathyroid disease is based on accurate biochemical diagnosis and the surgeon's understanding of the significant embryologic variations in parathyroid anatomy. An expert knowledge of the unusual anatomic locations for enlarged parathyroid glands is crucial to operative success during both initial and reoperative parathyroid surgical exploration. The wide range of parathyroid anatomic variations may make it difficult to predict a patient's anatomy preoperatively.",
"   </p>",
"   <p>",
"    Parathyroid anatomy is discussed here. The indications for parathyroidectomy, treatment of multiglandular disease, and surgical techniques are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of primary hyperparathyroidism\", section on 'Candidates for surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H10466865#H10466865\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Focused parathyroid exploration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parathyroid glands are usually in close approximation with, but function independently of, the thyroid gland. The parathyroid glands produce parathyroid hormone (PTH) which is one of the two major hormones modulating calcium and phosphate homeostasis; the other hormone is calcitriol (1,25-dihydroxyvitamin D). PTH also stimulates the conversion of calcidiol (25-hydroxyvitamin D) to calcitriol in renal tubular cells, thereby stimulating intestinal calcium absorption. The function and regulation of PTH and the diagnosis and management of hyperparathyroidism are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=see_link\">",
"     \"Parathyroid hormone secretion and action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parathyroid glands arise from endodermal epithelial cells, in conjunction with the thymus (",
"    <a class=\"graphic graphic_figure graphicRef75141 \" href=\"UTD.htm?9/60/10185\">",
"     figure 1",
"    </a>",
"    ). The superior parathyroid glands are derived from the fourth branchial pouch. These glands are closely associated with the lateral lobes of the thyroid and have a short line of embryologic descent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inferior parathyroid glands are derived from the third branchial pouch. These glands are closely associated with the thymus and have a longer line of embryologic descent, which leads to more variability in their anatomic position [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/4\">",
"     4",
"    </a>",
"    ]. Inferior parathyroids can be found as high in the neck as the carotid sheath and can also be found in the anterior mediastinum or even the pericardium. However, the majority of inferior parathyroids are found near the inferior pole of the thyroid.",
"   </p>",
"   <p>",
"    The locations of ectopic parathyroid glands are related to the common origins of parathyroid, thyroid, and thymic tissue. The third branchial pouch contributes to thymus development as well as parathyroid and thyroid development. Both the third and fourth branchial pouches also contribute to thyroid development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44310?source=see_link\">",
"     \"Surgical anatomy of the thyroid gland\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SIZE AND LOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal parathyroid glands are approximately the size of a grain of rice or a lentil. Normal glands are usually about 5 by 4 by 2 millimeters in size and weigh 35 to 50 milligrams (",
"    <a class=\"graphic graphic_picture graphicRef67975 \" href=\"UTD.htm?11/47/12020\">",
"     picture 1",
"    </a>",
"    ). Enlarged parathyroid glands can be 50 milligrams to 20 grams in weight, most typically weighing about 1 gram and 1 centimeter in size (",
"    <a class=\"graphic graphic_picture graphicRef55183 \" href=\"UTD.htm?23/21/23890\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The appearance of parathyroid glands can vary considerably [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The color varies from light yellow to reddish-brown. Most parathyroid glands (83 percent) are oval, bean shaped or spherical, but can also be elongated (11 percent). Other variations such as teardrop, pancake, rod-like, sausage, and leaf shaped parathyroid glands have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/6\">",
"     6",
"    </a>",
"    ]. Occasionally the glands are bi-lobated (5 percent) or multilobated (1 percent).",
"   </p>",
"   <p>",
"    Most (84 percent) patients have four parathyroid glands, two superior and two inferior glands [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/5\">",
"     5",
"    </a>",
"    ]. Additional glands are found in 13 percent of patients and only three glands in a very small number of patients (&le;3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/5\">",
"     5",
"    </a>",
"    ]. The terms \"superior\" and \"inferior\" refer to a gland's embryologic origin, rather than the gland's location in the neck. During parathyroid exploration, deductive reasoning based on the embryologic origin of identified parathyroid glands helps the surgeon identify missing glands (",
"    <a class=\"graphic graphic_figure graphicRef56752 \" href=\"UTD.htm?9/47/9972\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The parathyroids are usually in close association with the thyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/5\">",
"     5",
"    </a>",
"    ]. Although there is significant variability in the position of the glands, they are usually symmetric. The superior glands are symmetric in 80 percent of cases and inferior glands are symmetric 70 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Superior parathyroid glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal superior parathyroid glands are usually located on the posterior-lateral surface of the middle to superior thyroid lobe. They lie under the thyroid superficial fascia, posterior to the recurrent laryngeal nerve and can be visualized by carefully dissecting the thyroid capsule in this region. These glands also can reside inside the thyroid capsule, just superior and medial to the posterior tubercle of Zuckerkandl of the thyroid lobe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44310?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgical anatomy of the thyroid gland\", section on 'Tubercle of Zuckerkandl'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recurrent laryngeal nerve is always anterior to the superior parathyroid gland. The superior parathyroid glands are usually 1 to 2 centimeters cranial to the junction of the recurrent laryngeal nerve with the inferior thyroid artery and within one centimeter of the entry point for the recurrent laryngeal nerve into the ligament of Berry and the cricoid cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superior parathyroid glands can be undescended, or can be parapharyngeal, retropharyngeal, or retrotracheal within the middle",
"    <span class=\"nowrap\">",
"     cervical/mediastinal",
"    </span>",
"    compartment. Enlarged parathyroid glands can travel straight down the tracheoesophageal groove or the retropharyngeal space into the chest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inferior parathyroid glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two inferior parathyroid glands reside in the anterior mediastinal compartment, anterior to the recurrent laryngeal nerve. They are most often found in the thyrothymic tract, or just inside the thyroid capsule on the inferior portion of the thyroid lobes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ectopic parathyroid glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic parathyroid glands occur because parathyroid tissue may co-locate with tissues that have a similar embryologic development. An ectopic parathyroid gland that fails to have full migration during normal development is termed \"undescended.\" The ectopic gland may be one of the four parathyroid glands or it may be a supernumerary gland. In one series of 102 patients with persistent or recurrent hyperparathyroidism who required reoperation, ectopic glands were found in the paraesophageal position (28 percent), in the mediastinum (26 percent), intrathymic (24 percent), intrathyroidal (11 percent), in the carotid sheath (9 percent) and in a high cervical position (2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/7\">",
"     7",
"    </a>",
"    ]. These percentages will vary depending whether the ectopic gland is superior or inferior in origin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ectopic superior parathyroid glands &mdash; Most often a missing superior parathyroid gland will originate in a normal position but is difficult to find because caudal growth has moved the body of the adenoma to the paraesophageal or retroesophageal space. An ectopic superior parathyroid gland may be undescended and located at the piriform sinus. Superior parathyroid glands can be also be intrathyroidal, but less commonly than inferior parathyroid glands.",
"     </li>",
"     <li>",
"      Ectopic inferior parathyroid glands &mdash; Enlarged parathyroid glands can be undescended at the carotid bulb. More typically they will be found lateral and inferior to the middle to lower thyroid lobe adjacent to the thyrothymic tract, which extends inferiorly from the inferior thyroid poles. They may be subcapsular, or completely intrathyroidal or may reside within or in close proximity to the cervical or anterior mediastinal thymus. Ectopic inferior parathyroid glands are most often found in the thymus or mediastinum (9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/8\">",
"       8",
"      </a>",
"      ]. An undescended inferior parathyroid gland may be located anywhere within the carotid sheath (2 percent). They can also be located intrathyroidally (1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Supernumerary parathyroid glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supernumerary (more than four) parathyroid glands occur in 2.5 to 15 percent of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. The majority of supernumerary glands are small, rudimentary, or divided. However, when enlarged, these additional glands may be responsible for persistent hyperparathyroidism after failed parathyroid exploration, especially in patients with secondary hyperparathyroidism or hyperparathyroidism associated with familial syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ]. In one series of 137 cases of persistent hyperparathyroidism after parathyroidectomy, supernumerary glands were found in 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/9\">",
"     9",
"    </a>",
"    ]. They can range from 5 to 8 in number [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supernumerary glands can reside anywhere from behind the thyroid down to and including within the thymus, representing the line of descent of thymic tissue during embryologic development. The most common location is within the thymus or in relation to the thyrothymic ligament (two thirds of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. The remaining supernumerary glands are usually found in the vicinity of the mid-thyroid lobe between two other glands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     BLOOD SUPPLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, the inferior and superior parathyroid glands will both be supplied by branches of the inferior thyroid artery. Each parathyroid gland usually has its own end-artery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/4\">",
"     4",
"    </a>",
"    ]. Most parathyroid glands have a single arterial supply (80 percent), some have a dual artery supply (15 percent), and a minority have multiple arterial supply (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/12\">",
"     12",
"    </a>",
"    ]. The venous drainage of the parathyroid glands consists of the superior, middle, and inferior thyroid veins that drain into the internal jugular vein or the innominate vein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44310?source=see_link&amp;anchor=H10#H10\">",
"     \"Surgical anatomy of the thyroid gland\", section on 'Blood supply'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During thyroid surgery, the surgeon should try to preserve all of the parathyroid glands in situ with adequate blood supply whenever possible. However, the blood supply may not be adequate following dissection of the thyroid gland, and the parathyroids are not always clearly identified. It can be difficult to make a reliable intraoperative determination of individual parathyroid function and patients may experience transient hypoparathyroidism despite having all four parathyroid glands preserved.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superior parathyroid glands &mdash; The superior parathyroid glands receive most of their blood supply from the inferior thyroid artery and also are supplied by branches of the superior thyroid artery in 15 to 20 percent of patients. A superior parathyroid gland that is supplied by the superior thyroid artery will usually be located in close proximity to the superior pole of the thyroid. A subcapsular dissection on the posterior lateral surface can assist in the identification of parathyroid glands.",
"     </li>",
"     <li>",
"      Inferior parathyroid glands &mdash; The inferior parathyroid glands receive their end-arterial blood supply from the inferior thyroid artery. Therefore, gentle medial mobilization of the parathyroid rim from the thyroid capsule and preservation of the lateral arteriole going to the parathyroid gland is important for preserving functioning inferior parathyroid glands. Ligation of the branches of the inferior thyroid artery close to the thyroid parenchyma and medial to the recurrent laryngeal nerve may help preserve intact parathyroid vascularity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MISSING PARATHYROID GLANDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A missed parathyroid adenoma is the most common cause for a failed initial parathyroid operation and persistent hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29045/abstract/13\">",
"     13",
"    </a>",
"    ]. During exploration for primary hyperparathyroidism, understanding the embryology and anatomy of the parathyroid glands will help determine which one of the four parathyroid glands is missing or whether a supernumerary gland is present. Surgical exploration for a missed or ectopic parathyroid gland is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H28792404#H28792404\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Operative management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The success of the surgical management of parathyroid disease is based on accurate biochemical diagnosis and the surgeon's expert understanding of the significant embryologic variations in parathyroid anatomy. Knowledge of the unusual anatomic locations for enlarged parathyroid glands is crucial to operative success during both initial and reoperative parathyroid surgery. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The superior parathyroid glands are derived from the fourth branchial pouch. The inferior parathyroid glands are derived from the third branchial pouch. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Embryology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most (84 percent) individuals have four parathyroid glands, two superior and two inferior glands. The terms \"superior\" and \"inferior\" refer to a gland's embryologic origin, rather than the gland's location in the neck. During parathyroid exploration, deductive reasoning based on the embryologic origin of identified parathyroid glands helps the surgeon identify missing glands. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Size and location'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ectopic parathyroid glands occur because parathyroid tissue may co-locate with tissues that have a similar embryologic development. The ectopic gland may be one of the four parathyroid glands or it may be a supernumerary gland. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ectopic parathyroid glands'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supernumerary (more than four) parathyroid glands may be responsible for persistent hyperparathyroidism after failed parathyroidectomy. Supernumerary glands can reside anywhere from behind the thyroid down to and including within the thymus, representing the line of descent of thymic tissue during embryologic development. The most common location is within the thymus or in relation to the thyrothymic ligament. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Supernumerary parathyroid glands'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most patients, the inferior and superior parathyroid glands will both be supplied by branches of the inferior thyroid artery. Each parathyroid gland usually has its own end-artery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Blood supply'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A missed parathyroid adenoma is the most common cause for a failed initial parathyroid operation and persistent hyperparathyroidism. Understanding the embryology and anatomy of the parathyroid glands will help determine which one of the four parathyroid glands is missing or if it is a supernumerary gland. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H1352796#H1352796\">",
"       \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Missing parathyroid glands'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/1\">",
"      Owen, R. On the anatomy of the Indian Rhinoceros (Rh. Unicornis, L). Trans Zool Soc Lond 1862;  4:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/2\">",
"      Sandstr&ouml;m, I. On a new gland in man and several mammals (glandulae parathyroideae). Ups L&auml;k F&ouml;rh 1880;  15:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/3\">",
"      Mandl, F. Therapeutischer versuch bein einem falle von ostitis fibrosa generalisata mittels exstirpation eines epithelk orperchen tumors. Zentrabl Chir 1926;  5:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/4\">",
"      Bliss RD, Gauger PG, Delbridge LW. Surgeon's approach to the thyroid gland: surgical anatomy and the importance of technique. World J Surg 2000; 24:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/5\">",
"      Akerstr&ouml;m G, Malmaeus J, Bergstr&ouml;m R. Surgical anatomy of human parathyroid glands. Surgery 1984; 95:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/6\">",
"      Wang C. The anatomic basis of parathyroid surgery. Ann Surg 1976; 183:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/7\">",
"      Shen W, D&uuml;ren M, Morita E, et al. Reoperation for persistent or recurrent primary hyperparathyroidism. Arch Surg 1996; 131:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/8\">",
"      Richards ML, Thompson GB, Farley DR, Grant CS. Reoperative parathyroidectomy in 228 patients during the era of minimal-access surgery and intraoperative parathyroid hormone monitoring. Am J Surg 2008; 196:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/9\">",
"      Carter WB, Carter DL, Cohn HE. Cause and current management of reoperative hyperparathyroidism. Am Surg 1993; 59:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/10\">",
"      Arveschoug AK, Br&oslash;chner-Mortensen J, Bertelsen H, Vammen B. Supernumerary parathyroid glands in recurrent secondary hyperparathyroidism. Clin Nucl Med 2002; 27:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/11\">",
"      Edis AJ, Levitt MD. Supernumerary parathyroid glands: implications for the surgical treatment of secondary hyperparathyroidism. World J Surg 1987; 11:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/12\">",
"      Flament, JB, Delattre, JF, Pluot, M. Arterial blood supply to the parathyroid glands: Implications for thyroid surgery. Surgical and Radiologic Anatomy 1982; 3:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29045/abstract/13\">",
"      Jaskowiak N, Norton JA, Alexander HR, et al. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg 1996; 224:308.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2156 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-DB4EA05A22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29045=[""].join("\n");
var outline_f28_23_29045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SIZE AND LOCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Superior parathyroid glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inferior parathyroid glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ectopic parathyroid glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Supernumerary parathyroid glands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BLOOD SUPPLY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MISSING PARATHYROID GLANDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2156|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/60/10185\" title=\"figure 1\">",
"      Coronal views of pharyngeal arch transformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/47/9972\" title=\"figure 2\">",
"      Parathyroid location",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2156|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/47/12020\" title=\"picture 1\">",
"      Normal parathyroid glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/21/23890\" title=\"picture 2\">",
"      Parathyroid adenoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=related_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=related_link\">",
"      Parathyroid hormone secretion and action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44310?source=related_link\">",
"      Surgical anatomy of the thyroid gland",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_23_29046="Equipment for LEEP";
var content_f28_23_29046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Equipment for loop electrosurgical excision procedure (LEEP) of uterine cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 455px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A-E) Loops of various sizes and (F) an electrosurgical generator.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29046=[""].join("\n");
var outline_f28_23_29046=null;
var title_f28_23_29047="Prednisone: Pediatric drug information";
var content_f28_23_29047=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prednisone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"    see \"Prednisone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"    see \"Prednisone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      PredniSONE Intensol&trade;;",
"     </li>",
"     <li>",
"      Rayos&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Prednisone&reg;;",
"     </li>",
"     <li>",
"      Novo-Prednisone;",
"     </li>",
"     <li>",
"      Winpred&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"      see \"Prednisone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose depends upon condition being treated and response of patient; dosage for infants and children should be based on disease severity and patient response rather than by rigid adherence to dosage guidelines by age, weight, or body surface area. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     NIH Asthma Guidelines (NAEPP, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Asthma exacerbations (emergency care or hospital doses): 1-2 mg/kg/day in 2 divided doses (maximum: 60 mg/day) until peak expiratory flow is 70% of predicted or personal best",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Short-course &ldquo;burst&rdquo; (acute asthma): 1-2 mg/kg/day in divided doses 1-2 times/day for 3-10 days; maximum dose: 60 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Burst should be continued until symptoms resolve or patient achieves peak expiratory flow 80% of personal best; usually requires 3-10 days of treatment (~5 days on average); longer treatment may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Long-term treatment: 0.25-2 mg/kg/day given as a single dose in the morning or every other day as needed for asthma control; maximum dose: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Asthma exacerbations (emergency care or hospital doses): 40-80 mg/day in divided doses 1-2 times/day until peak expiratory flow is 70% of predicted or personal best",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Short-course &ldquo;burst&rdquo; (acute asthma): 40-60 mg/day in divided doses 1-2 times/day for 3-10 days;",
"     <b>",
"      Note:",
"     </b>",
"     Burst should be continued until symptoms resolve and peak expiratory flow is at least 80% of personal best; usually requires 3-10 days of treatment (~5 days on average); longer treatment may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Long-term treatment: 7.5-60 mg daily given as a single dose in the morning or every other day as needed for asthma control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternative asthma dosing by age:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Short-course &ldquo;burst&rdquo; (acute asthma):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;1 year: 10 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1-4 years: 20 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     5-13 years: 30 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;13 years: 40 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Long-term treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;1 year: 10 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1-4 years: 20 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     5-13 years: 30 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;13 years: 40 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-inflammatory or immunosuppressive: 0.05-2 mg/kg/day divided 1-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nephrotic syndrome:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric Nephrology Panel recommendations (Hogg, 2000):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 2 mg/kg/day or 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day given every day in 1-3 divided doses (maximum dose: 80 mg/day) until urine is protein free or for 4-6 weeks; followed by maintenance dose: 2 mg/kg/dose or 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose given every other day in the morning; gradually taper and discontinue after 4-6 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     6-week daily therapy followed by 6-week alternate day therapy may induce a higher rate of long remission compared to the standard of 4 weeks of daily therapy followed by 4 weeks of alternate day therapy; however, a higher incidence of adverse effects may be seen with the longer regimen and the clinical benefit may be variable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Relapse: Use high-dose daily steroid regimen (listed above) until urine is protein free for 3 days; follow with maintenance-tapering course of alternate day therapy (maintenance dose listed above) for 4-6 weeks; subsequent therapy is determined by individual's response and number of relapses (Hogg, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     British Pediatric Nephrology Consensus Statement (Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, 1994):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First 3 episodes: Initial: 2 mg/kg/day or 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day given every day (maximum dose: 80 mg/day) until urine is protein free for 3 consecutive days (maximum dose: 28 days); followed by 1-1.5 mg/kg/dose or 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum: 60 mg/dose) given every other day for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Frequent relapses (long-term maintenance dose): 0.5-1 mg/kg/dose given every other day for 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults: Physiologic replacement: 4-5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 5-60 mg/day in divided doses 1-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 1 mg/mL (5 mL, 120 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PredniSONE Intensol&trade;: 5 mg/mL (30 mL) [dye free, sugar free; contains ethanol 30%, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rayos&reg;: 1 mg, 2 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer after meals or with food or milk to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of adrenocortical insufficiency; used for its anti-inflammatory or immunosuppressant effects",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PredniSONE may be confused with methylPREDNISolone, Pramosone&reg;, prazosin, prednisoLONE, PriLOSEC&reg;, primidone, promethazine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F213151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Congestive heart failure (in susceptible patients), hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Emotional instability, headache, intracranial pressure increased (with papilledema), psychic derangements (including euphoria, insomnia, mood swings, personality changes, severe depression), seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, facial erythema, petechiae, thin fragile skin, urticaria, wound healing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenocortical and pituitary unresponsiveness (in times of stress), carbohydrate intolerance, Cushing&rsquo;s syndrome, diabetes mellitus, fluid retention, growth suppression (in children), hypokalemic alkalosis, hypothyroidism enhanced, menstrual irregularities, negative nitrogen balance due to protein catabolism, potassium loss, sodium retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, pancreatitis, peptic ulcer (with possible perforation and hemorrhage), ulcerative esophagitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, alkaline phosphatase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Aseptic necrosis of femoral and humeral heads, muscle mass loss, muscle weakness, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture (particularly Achilles tendon), vertebral compression fractures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Exophthalmos, glaucoma, intraocular pressure increased, posterior subcapsular cataracts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactic reactions, diaphoresis, hypersensitivity reactions, infections, Kaposi&rsquo;s sarcoma",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prednisone or any component; serious infections, except septic shock or tuberculous meningitis; systemic fungal infections; varicella infections; live or live, attenuated virus vaccines (with immunosuppressive doses of corticosteroids)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth). Use with extreme caution in patients with respiratory tuberculosis or untreated systemic infections. Use with caution in patients with hypertension, heart failure, or renal impairment; long-term use has been associated with fluid retention and hypertension. Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to risk of GI bleeding and perforation. High-dose corticosteroids should not be used for management of head injury; increased mortality was observed in patients receiving high-dose I.V. methylprednisolone. Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids. Use with caution in patients with hepatic impairment, including cirrhosis; enhanced pharmacologic effect due to decreased metabolism and long-term use has been associated with fluid retention. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture; hypertrophic cardiomyopathy has been reported in premature neonates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with diabetes; corticosteroids may alter glucose regulation, leading to hyperglycemia. Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use; consider routine eye exams in chronic users. Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis. Use with caution in patients with thyroid dysfunction; changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients. Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. Use with caution in patients with thromboembolic tendencies or thrombophlebitis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be tapered slowly and carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Immunosuppression may occur; patients may be more susceptible to infections; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral or fungal infections, activate latent opportunistic infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use. Acute myopathy may occur with high doses, usually in patients with neuromuscular transmission disorders; myopathy may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed. Increased IOP may occur, especially with prolonged use; in children, increased IOP has been shown to be dose-dependent and produce a greater IOP in children &lt;6 years than older children (Lam, 2005). Rare cases of anaphylactoid reactions have been reported with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral solution contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use prednisone products containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Concentrated oral solution (Intensol&trade;) contains propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities, which can include metabolic acidosis, seizures, renal failure, and CNS depression; use dosage forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C19 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase serum concentrations of the active metabolite(s) of PredniSONE. PredniSONE may decrease the serum concentration of CycloSPORINE (Systemic). PredniSONE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease serum concentrations of the active metabolite(s) of PredniSONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease serum concentrations of the active metabolite(s) of PredniSONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of PredniSONE. Management: Consider prednisone dose reductions in patients receiving ritonavir, and monitor for increased prednisone levels/adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the therapeutic effect of PredniSONE. Growth hormone may reduce the conversion of prednisone to the active prednisolone metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tesamorelin: May decrease serum concentrations of the active metabolite(s) of PredniSONE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, D, folate, calcium, zinc, and phosphorus and decreased sodium",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F213086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Prednisone and prednisolone cross the human placenta. In the mother, prednisone is converted to the active metabolite prednisolone by the liver. Prior to reaching the fetus, prednisolone is converted by placental enzymes back to prednisone. As a result, the level of prednisone remaining in the maternal serum and reaching the fetus are similar; however, the amount of prednisolone reaching the fetus is ~8-10 times lower than the maternal serum concentration (healthy women at term). Some studies have shown an association between first trimester prednisone use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy.  Pregnant women exposed to prednisone for antirejection therapy following a transplant may contact the National Transplantation Pregnancy Registry (NTPR) at 215-955-4820. Women exposed to prednisone during pregnancy for the treatment of an autoimmune disease (eg, rheumatoid arthritis) may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, weight, serum electrolytes, glucose; children's height and growth",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Converted rapidly in the liver to prednisolone (active)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"      see \"Prednisone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; limit caffeine; do not decrease dose or discontinue without physician's approval",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hogg RJ, Portman RJ, Milliner D, et al, &ldquo;Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE),&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(6):1242-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/23/29047/abstract-text/10835064/pubmed\" id=\"10835064\" target=\"_blank\">",
"        10835064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review). American Academy of Pediatrics Committee on Drugs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/23/29047/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam DS, Fan DS, Ng JS, et al, \"Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,\"",
"      <i>",
"       Clin Experiment Ophthalmol",
"      </i>",
"      , 2005, 33(3):252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/23/29047/abstract-text/15932528/pubmed\" id=\"15932528\" target=\"_blank\">",
"        15932528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MB, \"Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119 Suppl 2:S166-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/23/29047/abstract-text/17332238/pubmed\" id=\"17332238\" target=\"_blank\">",
"        17332238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy CM, Coonce SL, and Simon PA, &ldquo;Treatment of Asthma in Children,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1991, 10(9):685-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/23/29047/abstract-text/1680599/pubmed\" id=\"1680599\" target=\"_blank\">",
"        1680599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians, &ldquo;Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(2):151-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/23/29047/abstract-text/8129444/pubmed\" id=\"8129444\" target=\"_blank\">",
"        8129444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12725 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-4874105216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29047=[""].join("\n");
var outline_f28_23_29047=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213098\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055060\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055053\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213075\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213060\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055064\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055063\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213155\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213151\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055067\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055052\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055051\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213138\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213069\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055069\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213086\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055059\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055050\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055066\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055058\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12725\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12725|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=related_link\">",
"      Prednisone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=related_link\">",
"      Prednisone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_23_29048="First step ladder";
var content_f28_23_29048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 638px\">",
"   <div class=\"ttl\">",
"    First step algorithm: The seven-level criterion ladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 618px; height: 733px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Level 1:",
"    </strong>",
"    Melanocytic lesions criteria. a) Pigment network (exception: dermatofibroma); b) Negative network; c) Pseudonetwork (facial skin); d) Streaks; e) Parallel pigment pattern (acral lesions on palms and soles); f) Aggregated globules; g) Homogeneous blue pigmentation.",
"    <br>",
"     <strong>",
"      Level 2:",
"     </strong>",
"     Basal cell carcinomas criteria. a) Arborizing blood vessels; b) Spoke wheel-like structures; c) Leaf-like areas; d) Large blue-gray ovoid nests; e) Multiple non-aggregated blue-gray globules; f) Ulceration.",
"     <br>",
"      <strong>",
"       Level 3:",
"      </strong>",
"      Seborrheic keratosis criteria. a) Multiple (3 or more) milia-like cysts; b) Comedo-like openings; c) Gyri and sulci (fissures and ridges); d) Fingerprint-like structures; e) Moth-eaten borders.",
"      <br>",
"       <strong>",
"        Level 4:",
"       </strong>",
"       Hemangioma/angioma/angiokeratoma. a) Red lacunae; b) Blue lacunae; c) Black lacunae.",
"       <br>",
"        <strong>",
"         Level 5:",
"        </strong>",
"        Blood vessels as seen in non-melanocytic tumors. a) Arborizing vessels; b) Glomerular vessels; c) Hairpin vessels with white halo; d) Crown vessels; e) Serpiginous or string of pearls; f) \"Strawberry\" pattern.",
"        <br>",
"         <strong>",
"          Level 6:",
"         </strong>",
"         Blood vessels as seen in melanocytic tumors. a) Comma-shaped vessels; b) Dotted vessels; c) Serpentine vessels (or linear irregular); d) Corkscrew vessels; e) Polymorphous vessels; f) Milky-red areas.",
"         <br>",
"          <strong>",
"           Level 7:",
"          </strong>",
"          Structureless lesions. No structures or vessels noted.",
"          <div class=\"footnotes\">",
"          </div>",
"          <div class=\"reference\">",
"           Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"          </div>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29048=[""].join("\n");
var outline_f28_23_29048=null;
var title_f28_23_29049="Anterior cerebral artery territory";
var content_f28_23_29049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Anterior cerebral artery distribution and signs and symptoms of occlusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 578px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kistler, JP, et al, Cerebrovascular Diseases, Harrison's Principles of Internal Medicine, 13th ed. McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29049=[""].join("\n");
var outline_f28_23_29049=null;
var title_f28_23_29050="Prevention of HIV transmission during breastfeeding in resource-limited settings";
var content_f28_23_29050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of HIV transmission during breastfeeding in resource-limited settings",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/23/29050/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/23/29050/contributors\">",
"     Grace John-Stewart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/23/29050/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/23/29050/contributors\">",
"     Lynne M Mofenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/23/29050/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/23/29050/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/23/29050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1758078\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mother-to-child HIV-1 transmission occurs in utero, peripartum, and postnatally via breastfeeding; without interventions the risk of perinatal HIV-1 transmission is 20 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the past two decades, clinical trials have demonstrated that the risk of mother-to-child transmission can be significantly reduced with the administration of short-course antiretroviral medications during pregnancy, delivery, and the early postpartum period (eg, two to four weeks after delivery) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. However, excess HIV transmission has been observed among breastfeeding infants after short-term prophylactic strategies are completed following delivery. Since breastfeeding is important for the nutritional and overall health of the infant, subsequent studies have been designed to evaluate the role of antiretroviral medications during the postnatal period in preventing HIV transmission during breastfeeding.",
"   </p>",
"   <p>",
"    This topic will discuss clinical data from resource-limited settings on the prevention of HIV transmission during the breastfeeding period. Advice on the use of antepartum and intrapartum antiretroviral prophylaxis for prevention of mother-to-child HIV transmission in low to mid-resource countries are discussed in detail in the 2010 World Health Organization guidelines on Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infections in Infants (",
"    <a class=\"external\" href=\"file://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html\">",
"     file://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1758085\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF HIV TRANSMISSION THROUGH BREASTFEEDING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1808791\">",
"    <span class=\"h2\">",
"     Risk of breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 90 percent of HIV infections in infants occur in sub-Saharan Africa; approximately 40 percent of these infections occur during the postnatal period. According to a 2007 report from the World Health Organization (WHO), approximately 200,000 infants worldwide become infected annually with HIV through breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/6\">",
"     6",
"    </a>",
"    ]. Early evidence for HIV transmission via breast milk included higher rates of mother-to-infant HIV transmission in regions where women mostly breastfed (eg, Africa) than in areas where they mainly replacement fed (United States and Europe) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/1\">",
"     1",
"    </a>",
"    ]. There have also been reports of infection in infants born to HIV-uninfected mothers but breastfed by HIV-infected surrogates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/7\">",
"     7",
"    </a>",
"    ]. Additionally, there have been rare reports of HIV transmission from nosocomially-infected (eg, through blood transfusion) infants to HIV-uninfected mothers through breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/8\">",
"     8",
"    </a>",
"    ]. In such cases, transmission likely occurs as a result of breastfeeding contact during a period of epithelial disruption such as maternal skin fissures or infant stomatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76014255\">",
"    <span class=\"h2\">",
"     Estimating the risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-1 detection in infants during the first two weeks of life may represent transmission that has occurred in utero, during delivery, or within the early days of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/9\">",
"     9",
"    </a>",
"    ]. This complicates estimation of early breast milk HIV transmission risk during the first month of life. Most studies that have evaluated the risk of infant acquisition of HIV infection through breastfeeding have begun data collection at one month of life to avoid this overlap of potential transmission routes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76014262\">",
"    <span class=\"h2\">",
"     Biologic plausibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biologic plausibility of HIV transmission via breastfeeding was supported by the detection of HIV-1 RNA in colostrum and breast milk, and through evidence linking transmission of other viruses through breast milk (eg, human T-cell leukemia virus) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Some studies suggest that HIV-infected cells within breast milk may play a more important role in infant transmission than cell-free virus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1808798\">",
"    <span class=\"h2\">",
"     Risk of replacement feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the first report of breast milk HIV transmission in the United States, the Centers for Disease Control (CDC) issued guidelines recommending replacement feeding for HIV-uninfected infants born to HIV-infected mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in developing countries, replacement feeding is associated with other significant risks, such as increased infant morbidity and mortality from diarrheal disease, pneumonia, and other infectious diseases, thus limiting the utility of this option [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Decreased rates of overall morbidity and mortality in infants who breastfeed have been attributed to [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protective antibodies, which are passed from mother to infant within the first few months of life",
"     </li>",
"     <li>",
"      Decreased exposure to infectious pathogens via unsafe water",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1809716\">",
"    <span class=\"h1\">",
"     MECHANISM OF BREAST MILK HIV TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The portal of entry of HIV in the breastfed infant has not been defined, but may include the intestine or tonsillar tissues. Breaches in intestinal epithelial integrity or compromise in intestinal cellular tight junctions (eg, between epithelial or dendritic cells) may allow entry of infectious virions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. The possibility of HIV entry into tonsillar lymphocytes has been suggested from studies of a related virus (ie, simian immunodeficiency virus) in infant macaques [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1758092\">",
"    <span class=\"h1\">",
"     TIMING OF BREAST MILK HIV TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early clinical trial data suggested that the risk is highest in early months of the infant&rsquo;s life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Nairobi trial, which evaluated rates of HIV infant transmission among breastfeeding and replacement feeding infants, found that 67 percent of the risk difference between the two trial arms occurred by two months while 75 percent occurred within six months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Malawian cohort of 672 mother-infant pairs found that the HIV transmission risk declined as breastfeeding continued: 0.7",
"      <span class=\"nowrap\">",
"       percent/month",
"      </span>",
"      (months 1 through 5); 0.6",
"      <span class=\"nowrap\">",
"       percent/month",
"      </span>",
"      (months 6 through 11), and 0.3",
"      <span class=\"nowrap\">",
"       percent/month",
"      </span>",
"      (months 12 through 17) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis (Breastfeeding and HIV International Transmission Study) suggested that the risk of late breast milk transmission (postnatal transmission occurring after one month of age) appeared relatively constant at 8.9 transmissions per 100 person-years of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1758099\">",
"    <span class=\"h1\">",
"     COFACTORS FOR BREAST MILK HIV TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cofactors that may affect HIV transmission to the infant include the mother&rsquo;s immunologic status, presence of mastitis, and patterns of feeding. However, clinical and laboratory data suggest that the most prominent factor may be the level of viremia in the mother. The level of viremia has also been shown to be a good surrogate for mother to child transmission risk in clinical trials of maternal antiretroviral prophylaxis for postnatal HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1758107\">",
"    <span class=\"h2\">",
"     Virologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher breast milk HIV DNA and RNA levels are associated with increased transmission risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] as demonstrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a longitudinal assessment of 275 Kenyan HIV-1 infected mothers, a log increase of breast milk HIV RNA was associated with twofold higher risk of HIV transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of several observational studies found that the risk of HIV transmission was significantly higher among women with acute versus chronic HIV infection (29 versus 14 percent). This observation may be related to the level of HIV RNA, which is generally much higher in acute HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1758099\">",
"       'Cofactors for breast milk HIV transmission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1758114\">",
"    <span class=\"h2\">",
"     Immunologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have noted increased transmission among immunosuppressed women with low CD4 counts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/1\">",
"     1",
"    </a>",
"    ]. This observation may be related to the higher viral burden in patients with advanced HIV disease, but maternal or infant immune status may confer some independent influence on transmission as well. &nbsp;",
"   </p>",
"   <p>",
"    Both HIV-1 specific immunoglobulins (IgA and IgM) and HIV-1 specific cytotoxic T-cells are detected in breast milk; their potential roles in preventing HIV transmission through breastfeeding are under active investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one observational study in South Africa, the presence of HIV-specific T-helper cells in cord blood was associated with decreased intrapartum and postnatal HIV transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective cohort of 217 HIV-seronegative Kenyan infants, a higher magnitude of interferon production by HIV-specific T-cells was associated with a decreased risk of HIV transmission via breastfeeding over 12 months of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Secretory leukocyte protease inhibitor (SLPI) is a protein found in saliva, breast milk and genital secretions, which is capable of inhibiting HIV in vitro. Higher levels of salivary leukocyte protease inhibitor (SLPI) in infant saliva have been associated with a lower risk of HIV acquisition [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/35\">",
"       35",
"      </a>",
"      ] while SLPI levels in breast milk do not appear to modify transmission rates [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/20,36,37\">",
"       20,36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1758121\">",
"    <span class=\"h2\">",
"     Breast infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastitis and breast abscess have been associated with an increased risk of HIV transmission, which may be due to the increased recruitment of HIV-infected inflammatory cells in an area of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/29,38-42\">",
"     29,38-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4733392\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF ANTIRETROVIRAL MEDICATIONS IN PREVENTING INFANT HIV TRANSMISSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4733597\">",
"    <span class=\"h2\">",
"     Role of antiretroviral medications during antepartum, intrapartum and early postpartum period",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected women may need antiretroviral medications for their own health during pregnancy and should be treated regardless of age of gestation. In addition, women who do not need antiretroviral therapy for their own health are still candidates to receive antiretroviral medications for the sole purpose of preventing mother to child transmission (MTCT) of HIV infection during pregnancy, delivery, and the early postpartum period (eg, two to four weeks after delivery).",
"   </p>",
"   <p>",
"    Clinical trials have demonstrated that the use of antiretroviral medications during pregnancy, labor, and delivery effectively reduces intrauterine and intrapartum HIV transmission from 24 percent to approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4733676\">",
"    <span class=\"h2\">",
"     Role of antiretroviral medications during the breastfeeding period",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without ongoing prophylaxis after delivery, one meta-analysis demonstrated that an additional 9 percent of infants who are born to HIV-seropositive mothers will become infected during the late postnatal period through breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/45\">",
"     45",
"    </a>",
"    ]. Fortunately, large randomized clinical trials now demonstrate that the risk of postnatal HIV transmission can be substantially lowered with the continued use of antiretroviral medications by the mother or the infant during the breastfeeding period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1809829\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS OF ANTIRETROVIRAL DRUGS TO PREVENT HIV TRANSMISSION THROUGH BREASTFEEDING",
"    </span>",
"   </p>",
"   <p>",
"    Observational and randomized trials in resource-limited settings have shown that administration of antiretroviral medications to the mother or infant during the postpartum period reduce rates of HIV transmission to the breastfeeding infant to less than 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Most of the breastfeeding trials were performed by randomly assigning patients who had completed peripartum antiretroviral prophylaxis to either continue or discontinue antiretroviral prophylaxis through the breastfeeding period.",
"   </p>",
"   <p>",
"    The discussion below highlights some of the main concepts that have emerged within the last several years regarding the most effective use of antiretroviral medications for the prevention of HIV during breastfeeding. Some of the drugs that have been studied include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , which is a nonnucleoside reverse transcriptase inhibitor (NNRTI);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , which are nucleoside reverse transcriptase inhibitors (NRTIs); and",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    (co-formulated as Kaletra), which are protease inhibitors (PIs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1809848\">",
"    <span class=\"h2\">",
"     Infant antiretroviral prophylaxis to prevent HIV acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have demonstrated the success of infant antiretroviral prophylaxis in decreasing the risk of HIV acquisition during breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/5,46-48\">",
"     5,46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a pooled analysis of data from 5396 mother-infant pairs included in five randomized trials that evaluated the prevention of HIV transmission during breastfeeding, a longer duration of infant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    prophylaxis was associated with a greater reduction in the risk of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/49\">",
"     49",
"    </a>",
"    ]. This study included the following trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Breastfeeding, Antiretrovirals, and Nutrition (BAN) trial in Malawi &ndash; Infants were given single-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      at birth followed by seven days of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"       zidovudine-lamivudine",
"      </a>",
"      and were randomly assigned to receive no further antiretroviral prophylaxis or an additional 28 weeks of nevirapine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Postexposure Prophylaxis of the Infant (PEPI) trial in Malawi &ndash; Infants were given single-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      at birth followed by seven days of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      and were randomly assigned to receive no further antiretroviral prophylaxis, an additional 14 weeks of nevirapine, or an additional 14 weeks of nevirapine plus zidovudine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The three Six-Week Extended",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       Nevirapine",
"      </a>",
"      (SWEN) trials in Ethiopia, India, and Uganda &ndash; Infants were given single-dose nevirapine at birth and were randomly assigned to receive no further antiretroviral prophylaxis or an additional six weeks of nevirapine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants born to mothers with CD4 cell counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    were excluded from the analysis as were infants found to be HIV-infected at birth. The risk of infection by 28 weeks ranged from 1.8 percent in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    arm of the BAN trial to 9.1 percent in the control arm of the PEPI trial. When given for 14 and 28 weeks, nevirapine was associated with a 61 and 71 percent reduction, respectively, in the risk of infant HIV infection at 28 weeks compared with the control groups in all five trials. A risk reduction was not observed with six weeks of nevirapine. &nbsp;",
"   </p>",
"   <p>",
"    This finding was confirmed in a subsequent clinical trial of 1527 breastfeeding infants born to HIV-infected mothers in four African countries that evaluated the incremental benefit of extended",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/48\">",
"     48",
"    </a>",
"    ]. All infants received nevirapine from birth to six weeks; subsequently the infants were randomly assigned to either extended nevirapine prophylaxis or placebo until six months of follow-up or until breastfeeding cessation, whichever came first. Compared with placebo, extended nevirapine prophylaxis reduced mother to child transmission of HIV by 54 percent (ie, 2.4 percent placebo versus 1.1 percent extended nevirapine, p = 0.049, respectively).",
"   </p>",
"   <p>",
"    As illustrated by the results of these trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    is effective as a single prophylactic agent and does not appear to have significant safety concerns when used in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/5,47\">",
"     5,47",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    does not add any additional benefit for prevention of transmission and may increase the risk of anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1809884\">",
"    <span class=\"h2\">",
"     Maternal antiretroviral drug use to prevent infant HIV transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there is a significant association between the level of the mother&rsquo;s viral load and HIV infant transmission, some studies have evaluated whether antiretroviral medications can lead to maternal viral suppression with a subsequent decline in MTCT during the breastfeeding period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/4,50\">",
"     4,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Mma Bana trial in Botswana, 560 women with CD4 counts of 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or more were randomly assigned to receive either triple nucleoside reverse transcriptase inhibitors (NRTIs) (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ), or a protease inhibitor (PI) containing regimen (ie,",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    with zidovudine and lamivudine) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/4\">",
"     4",
"    </a>",
"    ]. Antiretroviral prophylaxis was initiated between 26 and 34 weeks of gestation and continued through weaning or six months postpartum (ie, whichever occurred first). All infants also received short-term postnatal antiretroviral medications to prevent intrapartum MTCT of HIV (ie, single-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    at birth and zidovudine from birth through four weeks). Women with advanced immunosuppression (ie, CD4 cell counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    were placed in the observational group and were initiated on chronic antiretroviral therapy (ie, nevirapine, zidovudine, and lamivudine) for their own overall health. The primary endpoint was the proportion of women with viral suppression at delivery and up to six months postpartum; the level of HIV RNA is considered a good surrogate of transmission risk.",
"   </p>",
"   <p>",
"    High rates of maternal viral suppression to &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    were seen in both groups (96 percent in the NRTI group versus 93 percent in the PI group). The overall rate of mother-to-child transmission was 1.1 percent, the lowest rate ever reported in Africa. This rate is also similar to that seen among treated women in resource-rich settings who did not breastfeed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/4,51\">",
"     4,51",
"    </a>",
"    ]. Because of the low number of maternal-infant transmissions (ie, eight cases total), the effect of specific immunologic or virologic thresholds (eg, CD4 cell counts or HIV RNA levels) on the risk of transmission could not be analyzed. Rates of adverse events were similar in the NRTI and PI groups (6 percent each). However, there was a significantly higher rate of preterm delivery in the PI group than the NRTI group (23 vs 15 percent, respectively).",
"   </p>",
"   <p>",
"    Other studies have found somewhat higher overall transmission rates of approximately 3 to 5 percent with use of triple antiretroviral regimens in breastfeeding women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/2,52\">",
"     2,52",
"    </a>",
"    ]. For example, an observational study in Mozambique of HIV-infected mothers who were provided antenatal and postnatal antiretroviral medications for six months (mainly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ) demonstrated an overall HIV infant transmission rate of 2.8 percent at 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have also examined whether maternal antiretroviral drug interventions during breastfeeding can prevent HIV transmission among women with higher CD4 cell counts (eg, &gt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    rather than restricting its use to women with greater degrees of immunosuppression. Data from the Kesho Bora trial suggest that the benefit of maternal antiretroviral medications in reducing infant HIV transmission occurred among those women in the 200 to 350 cell strata, but not among women with a CD4 cell count above this threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1809914\">",
"    <span class=\"h2\">",
"     Maternal versus infant antiretroviral prophylaxis to reduce HIV transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Breastfeeding, Antiretrovirals, and Nutrition (BAN) trial was the first to assess the relative effectiveness of maternal or infant antiretroviral interventions compared with controls for prevention of HIV transmission to infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/5\">",
"     5",
"    </a>",
"    ]. In this large trial, mother-infant pairs were randomly assigned at delivery to a maternal regimen group, an infant regimen group, or neither intervention (the control group). Mothers who were enrolled had a CD4 cell count of 250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or higher. The infant regimen included daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    alone for 28 weeks; the maternal combination drug regimen varied during the trial due to emerging safety data related to individual agents (eg, hypersensitivity reactions and nevirapine use in women with CD4 counts &gt;250 cells). Most of the women in the trial received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (coformulated as Combivir), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted lopinavir (coformulated as Kaletra).",
"   </p>",
"   <p>",
"    In addition, perinatal antiretroviral prophylaxis (single-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    plus one week of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ) for the prevention of MTCT was given at delivery to all mothers and infants; based on the standard of care at the time, no antepartum prophylaxis was given. The women were advised to exclusively breastfeed during the study until 24 to 28 weeks when they were then instructed to rapidly wean. Maternal prophylaxis was discontinued one week after weaning. The primary efficacy endpoint was the rate of detection of HIV infection at 28 weeks among infants who were uninfected at two weeks of life between the two intervention arms compared to the control arm. Clinical and laboratory data were graded for severity of adverse events. On the basis of the fourth interim analysis, the data and safety monitoring board halted enrollment in the control group in 2008. &nbsp;",
"   </p>",
"   <p>",
"    The trial demonstrated that either a maternal regimen of combination antiretroviral medications or an infant regimen of daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    were both effective in reducing the risk of HIV transmission (cumulative postnatal risk 2.9 percent and 1.7 percent, respectively) compared with controls (5.7 percent). The effectiveness of infant prophylaxis was evident by six weeks, while the relative effectiveness of maternal prophylaxis was only first apparent at 12 weeks. This delayed effect in the maternal prophylaxis arm may be related to the time needed to attain maternal viral suppression, since ART was first initiated at delivery. The study protocol did not assess the association between HIV RNA detection and subsequent risk of infant transmission.",
"   </p>",
"   <p>",
"    A subsequent analysis of outcomes at 48 weeks demonstrated that, although the cumulative risk of HIV transmission still remained less in the maternal and infant prophylaxis arms (4 percent in both) than in the control group (7 percent), the 28 transmission events that occurred after 28 weeks were evenly distributed across all groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/53\">",
"     53",
"    </a>",
"    ]. Half of the late infections occurred at least 42 days after the reported cessation of breastfeeding. Furthermore, overall infant morbidity increased from 0.7 adverse events per 1000 person weeks during the intervention period to 1.1 events per 1000 person weeks after week 28, which correlated with the time when women weaned their infants. Although the study was not designed to evaluate the effect of early weaning, its results suggest that in resource-limited settings, instructing women to cease breastfeeding early at 24 to 28 weeks may not be an effective strategy against further HIV transmission and, as seen in other studies, may be associated with increased infant morbidity and mortality (see",
"    <a class=\"local\" href=\"#H13613026\">",
"     'Shortened breastfeeding'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The antiretroviral regimens were relatively well tolerated; significant adverse events included a low rate of hypersensitivity reactions related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    in the infants (1.9 percent) and neutropenia (6.2 percent among mothers and 2.6 percent among infants). However, 6 of 39 women who initially received a nevirapine-containing regimen developed a hypersensitivity reaction, including two with Stevens-Johnson syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1158900\">",
"    <span class=\"h2\">",
"     Lessons learned from clinical trial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several important concepts have emerged from the clinical trial data discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84760941\">",
"    <span class=\"h3\">",
"     Viral suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal viral suppression is associated with a decreased risk of mother to infant transmission during the postpartum period. Antiretroviral strategies that focus on maternal interventions should be initiated during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/54\">",
"     54",
"    </a>",
"    ], rather than at delivery, to maximally reduce infant HIV transmission (as illustrated in the Mma Bana and BAN trials).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84760948\">",
"    <span class=\"h3\">",
"     Duration of postnatal antiretroviral regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no randomized clinical trial data regarding the optimal duration of administration of antiretroviral medications, most experts advise continuation of these drugs throughout the breastfeeding period and for one week after breastfeeding is completed, since there is still some residual risk of HIV infant transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84760922\">",
"    <span class=\"h3\">",
"     Timing of maternal antiretroviral prophylaxis for the prevention of HIV transmission during breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the clinical trials discussed above suggest that earlier initiation of combination antiretroviral drug regimens during pregnancy (rather than at delivery), is associated with a lower risk of infant transmission. This is most likely related to the time that it takes for combination ART to lead to complete viral suppression.",
"   </p>",
"   <p>",
"    For example, in the control group within the BAN trial, the highest risk of infant HIV infection occurred between the second and twelfth weeks of life, with a transmission rate of 3.6 percent. During this period of high risk, the infant regimen reduced postnatal HIV transmission down to 0.5 percent (ie, nine infections) while the maternal regimen reduced this rate to 1.7 percent (ie, 34 infections). After 18 weeks of age, the incremental risk of infection was similar between the two arms. This suggests that earlier initiation of antiretroviral prophylaxis during pregnancy may further decrease the risk of infant HIV transmission.",
"   </p>",
"   <p>",
"    Although there are no randomized clinical trial data on any incremental benefit of earlier ART interventions, the World Health Organization (WHO) recommends initiation of ART by 14 weeks of gestation, based on some observational studies showing benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159929\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS OF ANTIRETROVIRAL MEDICATIONS DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal regimen to prevent the transmission of HIV from mother to infant during the perinatal and postnatal period may be affected by the pharmacokinetics of various antiretroviral medications during pregnancy and the ability of these medications to decrease shedding of HIV RNA in breast milk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For example, in the Mma Bana trial, when using a more sensitive HIV RNA assay (limit of detection &lt;50",
"      <span class=\"nowrap\">",
"       copies/mL),",
"      </span>",
"      rates of viral suppression at delivery were significantly higher in women assigned to the NRTI arm compared with the PI arm (81 versus 69 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/4\">",
"       4",
"      </a>",
"      ]. Although serum drug levels were not assayed for",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      in this trial, some pharmacokinetic studies have suggested that drug concentrations of this medication may be subtherapeutic during the third trimester of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. One pharmacokinetic study suggests that increased dosing of",
"      <span class=\"nowrap\">",
"       lopinavir/ritonavir",
"      </span>",
"      during the third trimester can lead to therapeutic drug levels, although there is no consensus yet on the optimal dosing in pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=see_link\">",
"       \"Antiretroviral medications in pregnancy: Protease inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In another study, mothers who received single-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      had significantly lower HIV RNA levels in their breast milk compared with mothers who received antepartum and intrapartum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      ; this effect was observed for up to 21 days of follow-up and may be related to the long serum half-life of nevirapine compared with zidovudine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"       \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"       \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64402186\">",
"    <span class=\"h1\">",
"     DRUG TOXICITY CONCERNS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2568674\">",
"    <span class=\"h2\">",
"     Fetal and infant toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse birth outcomes, such as low birth weight and prematurity, have been an issue of concern with the use of antiretroviral medications during pregnancy, although the risk appears low [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/51\">",
"     51",
"    </a>",
"    ]. In the Mma Bana trial, prematurity was more common among infants born to mothers in the protease inhibitor arm compared to the NRTI arm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/4,60\">",
"     4,60",
"    </a>",
"    ]. No differences were noted between the arms with regard to low birth weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    have all been studied for infant HIV prophylaxis. Postnatal infant zidovudine is associated with hematologic toxicity and does not appear to provide any additive benefit in preventing transmission over nevirapine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/47\">",
"     47",
"    </a>",
"    ]. Infant prophylaxis with lamivudine was well tolerated in one open-label prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/61\">",
"     61",
"    </a>",
"    ]. In the BAN trial, a small percentage of infants receiving daily nevirapine (&lt;2 percent) developed a hypersensitivity reaction, which resolved in all cases with discontinuation of nevirapine and substitution of lamivudine as the infant prophylaxis regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2568681\">",
"    <span class=\"h2\">",
"     Risk of ART interruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from nonpregnant HIV-infected patients demonstrating increased morbidity with interruption of combination antiretroviral therapy led to the concern that initiating then discontinuing a triple-drug antiretroviral regimen in pregnant women could lead to similar adverse outcomes for the mother. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link&amp;anchor=H3394293#H3394293\">",
"     \"Structured treatment interruptions in the HIV-infected patient\", section on 'Treatment interruption in chronic HIV infection'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    This was evaluated in a post hoc analysis of the Kesho Bora trial, in which women were randomly assigned to receive",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"      zidovudine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"      lamivudine",
"     </a>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    from 28 to 34 weeks gestation until the cessation of breastfeeding (from 1 to 6.5 months postpartum) or prenatal zidovudine with single-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    at delivery and no postpartum antiretroviral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/62\">",
"     62",
"    </a>",
"    ]. The latter regimen had previously been shown to have no effect on the course of HIV disease. There was no difference in death or progression of HIV disease between the two arms 18 months following the cessation of antiretroviral agents (15 versus 14 percent in the triple drug and AZT groups, respectively). Thus, a several month course of combination ART does not appear to be associated with an excess of maternal HIV morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13613012\">",
"    <span class=\"h1\">",
"     PREVENTION OF HIV TRANSMISSION THROUGH CHANGES IN INFANT FEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Replacement feeding, shortened breastfeeding, and mixed feeding have been assessed to determine if alternative strategies in infant nutrition may limit the risk of HIV, in the absence of antiretroviral drug interventions. As discussed below, all of these approaches have their limitations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13613019\">",
"    <span class=\"h2\">",
"     Replacement feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance of breastfeeding is a certain way to prevent HIV transmission via breast milk during the postnatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a few areas with access to clean water supplies (eg, Nairobi), replacement feeding was associated with significantly lower rates of HIV transmission compared with those who breastfed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/64\">",
"     64",
"    </a>",
"    ]. However, this clinical trial preceded antiretroviral prophylaxis studies that demonstrated marked efficacy of decreasing transmission of HIV in both replacement feeding and breastfeeding women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Thus, in the context of antiretroviral medications, the benefits of replacement feeding (eg, improving HIV-free survival) are no longer retained [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/68\">",
"     68",
"    </a>",
"    ]. Furthermore, several observational studies from Africa have noted increased morbidity and mortality with replacement feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Finally, breastfeeding is associated with immunologic and survival benefits. (See",
"    <a class=\"local\" href=\"#H1808798\">",
"     'Risk of replacement feeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13613026\">",
"    <span class=\"h2\">",
"     Shortened breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested that a shortened course of breastfeeding may be somewhat protective against HIV infant transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/69\">",
"     69",
"    </a>",
"    ]. In order to limit the risk of HIV transmission and to facilitate the benefits of passive maternal antibody transfer, prior WHO guidelines recommended breastfeeding for a limited period of time (ie, six months). However, subsequent studies noted increased infant morbidity, mortality, and growth compromise with early breastfeeding cessation compared with longer periods of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Furthermore, HIV free survival was found to be similar in a study of Zambian Exclusive Breastfeeding, whether infants abruptly stopped breastfeeding at four months compared with those who continued for longer periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1758092\">",
"     'Timing of breast milk HIV transmission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Finally, with expanded antiretroviral drug availability in resource-limited settings, the risk of breast milk-associated HIV transmission becomes low, making early breastfeeding cessation relatively more risky than longer periods of breastfeeding, in terms of nutrition and other benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13613033\">",
"    <span class=\"h2\">",
"     Mixed feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;It might be anticipated that mixed feeding (eg, breastfeeding combined with other types of liquids or solids) might be associated with a lower risk of HIV transmission compared with exclusive breastfeeding due to less exposure to HIV-infected breastmilk. However, several studies from South Africa, Zambia, West Africa, and Zimbabwe have demonstrated that mixed feeding during the first three to six months of life is associated with an increased risk of infant HIV transmission compared with breastfeeding alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]. The reason for this observation is not well understood; some have suggested that infants may have greater exposure to infectious agents through liquids or solids, which compromise gut integrity, allowing for HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84761065\">",
"    <span class=\"h1\">",
"     ANTIRETROVIRAL DRUGS FOR THE PREVENTION OF PERINATAL HIV TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard of care is to also offer antiretroviral interventions to prevent perinatal HIV transmission (eg, antenatally, during delivery, and within the first few weeks after birth).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449181\">",
"    <span class=\"h1\">",
"     STRATEGIES TO PREVENT INFANT HIV TRANSMISSION DURING BREASTFEEDING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13613247\">",
"    <span class=\"h2\">",
"     WHO guidelines for infant feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 WHO guidelines recommend exclusive breastfeeding for six months, in combination with maternal or infant antiretroviral prophylaxis, to minimize HIV transmission from the mother and to optimize the benefits of breastfeeding for the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/19,55\">",
"     19,55",
"    </a>",
"    ]. Subsequently, breastfeeding, along with antiretroviral prophylaxis and appropriate complementary feeding, should continue for another six months given the increased infant morbidity associated with earlier weaning.",
"   </p>",
"   <p>",
"    Earlier studies suggested that exclusive breastfeeding was difficult to implement given cultural or logistic constraints with &lt;10 percent of women implementing exclusive breastfeeding despite counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/77,80\">",
"     77,80",
"    </a>",
"    ]. With expanded counseling and home visits, higher levels of exclusive breastfeeding are possible, with some studies reporting &gt;80 percent of HIV-1 infected women exclusively breastfeeding at three months postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13613306\">",
"    <span class=\"h2\">",
"     Choice of antiretroviral strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical trial data above demonstrate that both infant and maternal antiretroviral strategies are effective in reducing the risk of HIV transmission during breastfeeding. The specific strategy chosen will strongly depend on whether the mother requires life-long therapy for her own health. This is based on maternal CD4 cell count and World Health Organization (WHO) clinical stage, as discussed below.",
"   </p>",
"   <p>",
"    Use of combination antiretroviral medications for prophylaxis in women who do not require treatment for their own health may provide benefit to women during the period in which antiretroviral medications are received. However, this strategy is associated with greater cost, which can be prohibitive in certain developing countries. Additionally, it is unknown as to whether maternal exposure to combination antiretroviral medications during pregnancy and breastfeeding, followed by drug discontinuation (when HIV transmission risk has ceased), poses any risk to the mother.",
"   </p>",
"   <p>",
"    Infant prophylaxis during breastfeeding is generally less costly due to the use of a single drug compared with the use of combination drug regimens in the mother. A disadvantage of infant prophylaxis is the risk of HIV drug resistance if the infant does acquire infection during breastfeeding. However, since the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    prophylaxis among breastfeeding infants is high, the overall risk of drug resistance among infants receiving HIV prophylaxis is low. Also, the safety profile and cost of this intervention for infants is very favorable. Additionally, drug resistance has also been observed in infants who become infected despite maternal combination drug use during breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/81-83\">",
"     81-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of antiretroviral intervention, according to maternal HIV status, is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15492367\">",
"    <span class=\"h3\">",
"     Women who meet HIV treatment criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral therapy (ART) should be initiated at anytime during pregnancy if the mother requires HIV treatment for her own health status, regardless of gestational age. Early initiation of combination ART also decreases the risk of HIV transmission in utero, delivery, and the early post-partum period.",
"   </p>",
"   <p>",
"    The criteria for initiating ART for HIV infection among pregnant women are the same as for nonpregnant women. The WHO HIV treatment guidelines for patients in resource-limited settings include immunologic and clinical criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/84\">",
"     84",
"    </a>",
"    ]. Unlike in resource-rich settings, HIV RNA levels are not used as a treatment parameter since many developing countries do not have the resources for this kind of routine testing. Furthermore, the CD4 cell count thresholds for initiating treatment differ in resource-limited settings compared to resource-rich settings. The WHO recommends that women with a CD4 cell count of &lt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    should start ART antenatally for their own health, regardless of their clinical stage of disease. In addition, the WHO recommends ART initiation for women with WHO clinical stage 3 or 4 disease, irrespective of their CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/55\">",
"     55",
"    </a>",
"    ]. According to the WHO guidelines, HIV clinical stage 3 or 4 disease includes unexplained fevers, weight loss, chronic diarrhea, or a diagnosis of tuberculosis or an opportunistic infection. A complete listing of WHO HIV staging criteria is found in the table (",
"    <a class=\"graphic graphic_table graphicRef60340 \" href=\"UTD.htm?17/6/17517\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ART should be continued indefinitely in the woman who meets HIV treatment criteria, regardless of when breastfeeding is completed, to decrease the risk of HIV-related morbidity and mortality. The WHO 2010 guidelines suggest any of the following antiretroviral therapy options for women who require treatment for their own health [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The selection of specific antiretroviral medications for maternal HIV treatment will often depend on the country&rsquo;s formulary. Other considerations include efficacy, drug safety, and the pharmacokinetic profile of the specific antiretroviral medications during pregnancy. For example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    should not be given during the first trimester of pregnancy because of the risk of teratogenicity. The risk of hypersensitivity reactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    appear to be associated with CD4 cell counts &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    have comparable potency in patients with HIV RNA levels &lt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL;",
"    </span>",
"    however, in patients with higher levels of viremia, efavirenz may be preferred; however, efavirenz should not be used within the first trimester of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    are all well tolerated, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    is associated with a high incidence of anemia. Experience with tenofovir in pregnancy is more limited than for lamivudine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of chosen regimen or mode of infant feeding, the infant is also given four to six weeks of either daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    or twice-daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    prophylaxis to prevent HIV transmission during the early postpartum period (",
"    <a class=\"graphic graphic_table graphicRef70652 \" href=\"UTD.htm?35/22/36203\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15492385\">",
"    <span class=\"h3\">",
"     Women who do not meet HIV treatment criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected pregnant women who are not in need of treatment for their own health require effective antiretroviral prophylaxis to prevent HIV infection in their infants. For women with CD4 cell counts &gt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and WHO Stage 1 or 2 disease, either infant or maternal antiretroviral prophylaxis regimens are viable options to decrease the risk of HIV transmission during breastfeeding. WHO stage 1 disease includes asymptomatic individuals or those with persistent generalized lymphadenopathy. WHO stage 2 disease includes moderate unexplained weight loss, recurrent respiratory tract infections, herpes zoster, angular cheilitis, recurrent oral ulcerations, and dermatologic conditions (eg, seborrheic dermatitis) (",
"    <a class=\"graphic graphic_table graphicRef60340 \" href=\"UTD.htm?17/6/17517\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is also important for clinicians to understand that when the mother does not require HIV treatment, antiretroviral prophylaxis is still needed in the antepartum, intrapartum, and early postpartum periods to prevent mother-to-child transmission of HIV. Antepartum interventions should begin during the second trimester (as early as 14 weeks gestation), or as soon as possible thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO guidelines provide two different antepartum-intrapartum-postpartum options (Option A and Option B) for women who do not require treatment for their own health, which appear to be equally effective in reducing perinatal and postnatal HIV transmission (",
"    <a class=\"graphic graphic_table graphicRef51372 \" href=\"UTD.htm?36/29/37340\">",
"     table 3",
"    </a>",
"    ). WHO recommends that the choice of preferred options should be made at the country level [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64402577\">",
"    <span class=\"h4\">",
"     Option A",
"    </span>",
"    &nbsp;&mdash;&nbsp;This option includes a maternal antiretroviral regimen starting as early as 14 weeks gestation for the prevention of perinatal transmission and an infant antiretroviral regimen to prevent HIV transmission during breastfeeding (",
"    <a class=\"graphic graphic_table graphicRef51372 \" href=\"UTD.htm?36/29/37340\">",
"     table 3",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    prophylaxis should be given to breastfeeding infants starting at birth with the following dosing schedule (",
"    <a class=\"graphic graphic_table graphicRef65143 \" href=\"UTD.htm?40/35/41531\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Birth weight 2000 to 2499 g: 10 mg once daily",
"     </li>",
"     <li>",
"      Birth weight &gt;2500 g: 15 mg once daily",
"     </li>",
"     <li>",
"      &gt;6 weeks to 6 months: 20 mg once daily",
"     </li>",
"     <li>",
"      &gt;6 months to 9 months: 30 mg once daily",
"     </li>",
"     <li>",
"      &gt;9 months to end of breastfeeding: 40 mg once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benefits of this option include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low risk of adverse events with infant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      use",
"     </li>",
"     <li>",
"      If doses of drug are missed,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      can still be protective against infant HIV acquisition because of its long half-life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the maternal regimen is complex. In addition, NNRTI resistance in the infant is likely, if HIV transmission does occur. Finally, the safety and effectiveness of infant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    after six months of age is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64402601\">",
"    <span class=\"h4\">",
"     Option B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Option B includes potential maternal combination antiretroviral regimens for the prevention of infant HIV transmission among women who don&rsquo;t require treatment for their own health (",
"    <a class=\"graphic graphic_table graphicRef51372 \" href=\"UTD.htm?36/29/37340\">",
"     table 3",
"    </a>",
"    ). Although more costly, option B may be easier to implement compared to option A, since the same maternal regimen is used during the antepartum and postpartum periods. The WHO recommends any of the following selections for the mother:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antiretroviral prophylaxis should be started as early as 14 weeks gestation and discontinued one week after breastfeeding has stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/55\">",
"     55",
"    </a>",
"    ]. The selection of specific antiretroviral medications for maternal HIV prophylaxis of transmission will depend on the country&rsquo;s formulary, with other considerations including cost, efficacy, drug safety, and the pharmacokinetic profile of the specific antiretroviral medications during pregnancy. Issues related to antiretroviral drug use in pregnancy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10794?source=see_link\">",
"     \"Adverse effects of antiretroviral therapy in developing countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants born to mothers receiving combination antiretroviral prophylaxis should receive either daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    or twice daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    from birth until six weeks of age to prevent HIV transmission during the early postpartum period. Nevirapine dosing (",
"    <a class=\"graphic graphic_table graphicRef65143 \" href=\"UTD.htm?40/35/41531\">",
"     table 4",
"    </a>",
"    ) and zidovudine dosing (",
"    <a class=\"graphic graphic_table graphicRef72840 \" href=\"UTD.htm?11/16/11531\">",
"     table 5",
"    </a>",
"    ) are based on the weight of the infant.",
"   </p>",
"   <p>",
"    Should the infant become infected despite prophylaxis, multi-class drug resistance (NNRTI plus NRTI) may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Further data is needed on the risk of adverse pregnancy outcome (eg, prematurity) with antepartum triple antiretroviral drug prophylaxis. Finally, as with infant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , the safety and effectiveness of maternal antiretroviral prophylaxis after six months of age is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215891148\">",
"    <span class=\"h4\">",
"     Option B plus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, the WHO outlined a third option that consists of maternal initiation of one of the triple-drug antiretroviral regimens listed in Option B with lifelong continuation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/23/29050/abstract/85\">",
"     85",
"    </a>",
"    ]. Rationale for this option includes extended protection for future pregnancies, prevention of transmission to sexual partners, and probable benefits to the woman&rsquo;s own health, coupled with overall decreasing costs of antiretroviral regimens and increased operational feasibility in many countries. Nevertheless, this approach engenders many new challenges, including questions about long-term drug delivery and monitoring, adherence and resistance issues, as well as safety of longer term infant exposure to antiretroviral agents. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1158931\">",
"    <span class=\"h3\">",
"     Women who present late or during labor for care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who present late for perinatal care are at increased risk of transmitting HIV to their infant. In such cases, antepartum and intrapartum antiretroviral drug interventions should be given as soon as possible to prevent peripartum transmission (see",
"    <a class=\"external\" href=\"file://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html\">",
"     file://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html",
"    </a>",
"    ). Infant prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    should also be offered to prevent postnatal transmission in breastfeeding infants. Infant nevirapine is effective immediately against postnatal transmission, whereas maternal antiretroviral prophylaxis requires time to reduce viral load before it will be effective. After delivery, the woman will need evaluation to determine whether she requires treatment for her own health based on WHO treatment criteria.",
"    <span class=\"nowrap\">",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84760969\">",
"    <span class=\"h2\">",
"     Dosing of antiretroviral medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lopinavir/",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    administration during the last trimester has been associated with low serum drug levels in some studies. Some experts recommend higher doses of",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    during the third trimester of pregnancy based on a small pharmacokinetic study performed in the United States. Whether such an approach is safe among women in resource-limited settings has not been studied and is currently not recommended by the WHO. (See",
"    <a class=\"local\" href=\"#H1159929\">",
"     'Pharmacokinetics of antiretroviral medications during pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Dosing of other antiretroviral agents during pregnancy is similar to nonpregnant women; the availability of coformulations versus generic drugs influence dosing frequency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449464\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mother-to-child HIV-1 transmission occurs in utero, peripartum, and postnatally via breastfeeding; the risk of HIV transmission to the infant can be significantly reduced with antiretroviral medications. (See",
"      <a class=\"local\" href=\"#H1758078\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Replacement feeding is recommended for infants born to HIV-infected mothers in the United States, which is the current standard of care in resource-rich settings. However, in developing countries, replacement feeding is associated with greater infant morbidity and mortality from diarrheal disease, pneumonia, and other infectious diseases. (See",
"      <a class=\"local\" href=\"#H1758085\">",
"       'Epidemiology of HIV transmission through breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of HIV transmission through breast milk is greatest in the first several months of life; however, a lower but constant risk persists throughout the entire breastfeeding period. (See",
"      <a class=\"local\" href=\"#H1758092\">",
"       'Timing of breast milk HIV transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of infant transmission increases with increased levels of maternal HIV RNA in plasma or breast milk. (See",
"      <a class=\"local\" href=\"#H1758099\">",
"       'Cofactors for breast milk HIV transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiretroviral medications significantly decrease the risk of mother-to-child transmission of HIV during the antepartum, intrapartum, and early postpartum periods. However, an excess risk of HIV transmission occurs if antiretroviral medications are discontinued during the breastfeeding period. (See",
"      <a class=\"local\" href=\"#H4733392\">",
"       'Importance of antiretroviral medications in preventing infant HIV transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For HIV-infected mothers in resource-limited settings who are breastfeeding, we recommend postnatal antiretroviral medications for the mother or infant during the breastfeeding period, rather than no drug intervention (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The preferred interventional strategy will depend on the mother&rsquo;s CD4 cell count and HIV clinical status. (See",
"      <a class=\"local\" href=\"#H1809829\">",
"       'Clinical trials of antiretroviral drugs to prevent HIV transmission through breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among HIV-infected women with a CD4 cell count &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or with WHO stage 3 or 4 disease, antenatal combination antiretroviral therapy should be started as soon as feasible, regardless of gestational age and continued for the lifetime of the woman. This strategy leads to decreased risk of maternal morbidity and mortality and a decreased risk of HIV transmission to the infant during breastfeeding. (See",
"      <a class=\"local\" href=\"#H1809884\">",
"       'Maternal antiretroviral drug use to prevent infant HIV transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a CD4 cell count &gt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and WHO stage 1 or 2 disease, either neonatal or maternal prophylaxis is a viable option to prevent infant HIV transmission. Both interventions should be continued during the entire period of breastfeeding and for one week beyond discontinuation. Standard antiretroviral prophylaxis also needs to be offered for the prevention of mother-to-child transmission of HIV during the antepartum, intrapartum, and early postpartum periods. (See",
"      <a class=\"local\" href=\"#H15492385\">",
"       'Women who do not meet HIV treatment criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of agents will mainly depend on the country of origin, since formularies vary. (See",
"      <a class=\"local\" href=\"#H449181\">",
"       'Strategies to prevent infant HIV transmission during breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exclusive breastfeeding, in combination with maternal or infant ART, is recommended for the first six months of life as it leads to nutritional and immunologic benefits for the infant. Subsequently, breastfeeding, along with antiretroviral prophylaxis and appropriate complementary feeding, should continue for another six months given the increased infant morbidity associated with earlier weaning. (See",
"      <a class=\"local\" href=\"#H449181\">",
"       'Strategies to prevent infant HIV transmission during breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/1\">",
"      John GC, Kreiss J. Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiol Rev 1996; 18:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/2\">",
"      Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/3\">",
"      Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr Infect Dis J 2009; 28:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/4\">",
"      Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/5\">",
"      Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/child_adolescent_health/documents/9789241596596/en/index.html (Accessed on August 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/7\">",
"      Goedhals D, Rossouw I, Hallbauer U, et al. The tainted milk of human kindness. Lancet 2012; 380:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/8\">",
"      Little KM, Kilmarx PH, Taylor AW, et al. A review of evidence for transmission of HIV from children to breastfeeding women and implications for prevention. Pediatr Infect Dis J 2012; 31:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/9\">",
"      Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/10\">",
"      Van de Perre P, Lepage P, Homsy J, Dabis F. Mother-to-infant transmission of human immunodeficiency virus by breast milk: presumed innocent or presumed guilty? Clin Infect Dis 1992; 15:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/11\">",
"      Van de Perre P, Simonon A, Msellati P, et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. N Engl J Med 1991; 325:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/12\">",
"      Rousseau CM, Nduati RW, Richardson BA, et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis 2004; 190:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/13\">",
"      Koulinska IN, Villamor E, Chaplin B, et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr 2006; 41:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/14\">",
"      Centers for Disease Control (CDC). Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1985; 34:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/15\">",
"      Kuhn L, Stein Z. Infant survival, HIV infection, and feeding alternatives in less-developed countries. Am J Public Health 1997; 87:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/16\">",
"      Phadke MA, Gadgil B, Bharucha KE, et al. Replacement-fed infants born to HIV-infected mothers in India have a high early postpartum rate of hospitalization. J Nutr 2003; 133:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/17\">",
"      Homsy J, Moore D, Barasa A, et al. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2010; 53:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/18\">",
"      Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/19\">",
"      Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Lancet 2000; 355:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/20\">",
"      Lehman DA, Farquhar C. Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. Rev Med Virol 2007; 17:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/21\">",
"      Shen R, Smythies LE, Clements RH, et al. Dendritic cells transmit HIV-1 through human small intestinal mucosa. J Leukoc Biol 2010; 87:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/22\">",
"      Veazey R, Lackner A. The mucosal immune system and HIV-1 infection. AIDS Rev 2003; 5:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/23\">",
"      Lapenta C, Boirivant M, Marini M, et al. Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur J Immunol 1999; 29:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/24\">",
"      Abel K, Pahar B, Van Rompay KK, et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol 2006; 80:6357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/25\">",
"      Milush JM, Kosub D, Marthas M, et al. Rapid dissemination of SIV following oral inoculation. AIDS 2004; 18:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/26\">",
"      Nduati R, Mbori-Ngacha D, John G, et al. Breastfeeding in women with HIV. JAMA 2000; 284:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/27\">",
"      Miotti PG, Taha TE, Kumwenda NI, et al. HIV transmission through breastfeeding: a study in Malawi. JAMA 1999; 282:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/28\">",
"      Breastfeeding and HIV International Transmission Study Group, Coutsoudis A, Dabis F, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/29\">",
"      John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/30\">",
"      Sabbaj S, Ghosh MK, Edwards BH, et al. Breast milk-derived antigen-specific CD8+ T cells: an extralymphoid effector memory cell population in humans. J Immunol 2005; 174:2951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/31\">",
"      Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003; 187:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/32\">",
"      Van de Perre P, Simonon A, Hitimana DG, et al. Infective and anti-infective properties of breastmilk from HIV-1-infected women. Lancet 1993; 341:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/33\">",
"      Kuhn L, Coutsoudis A, Moodley D, et al. T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS 2001; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/34\">",
"      John-Stewart GC, Mbori-Ngacha D, Payne BL, et al. HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis 2009; 199:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/35\">",
"      Farquhar C, VanCott T, Bosire R, et al. Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya. Clin Exp Immunol 2008; 153:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/36\">",
"      Farquhar C, Mbori-Ngacha DA, Redman MW, et al. CC and CXC chemokines in breastmilk are associated with mother-to-child HIV-1 transmission. Curr HIV Res 2005; 3:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/37\">",
"      Tiemessen CT, Kuhn L. CC chemokines and protective immunity: insights gained from mother-to-child transmission of HIV. Nat Immunol 2007; 8:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/38\">",
"      Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/39\">",
"      Semba RD, Kumwenda N, Taha TE, et al. Mastitis and immunological factors in breast milk of lactating women in Malawi. Clin Diagn Lab Immunol 1999; 6:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/40\">",
"      Semba RD, Kumwenda N, Taha TE, et al. Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women. J Hum Lact 1999; 15:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/41\">",
"      Semba RD, Neville MC. Breast-feeding, mastitis, and HIV transmission: nutritional implications. Nutr Rev 1999; 57:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/42\">",
"      Willumsen JF, Filteau SM, Coutsoudis A, et al. Breastmilk RNA viral load in HIV-infected South African women: effects of subclinical mastitis and infant feeding. AIDS 2003; 17:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/43\">",
"      Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/44\">",
"      Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/45\">",
"      Leroy V, Newell ML, Dabis F, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV. Lancet 1998; 352:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/46\">",
"      Six Week Extended-Dose Nevirapine (SWEN) Study Team, Bedri A, Gudetta B, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/47\">",
"      Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/48\">",
"      Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 379:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/49\">",
"      Hudgens MG, Taha TE, Omer SB, et al. Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Clin Infect Dis 2013; 56:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/50\">",
"      Taha TE, Kumwenda J, Cole SR, et al. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J Infect Dis 2009; 200:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/51\">",
"      Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011; :CD003510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/52\">",
"      Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8:e1001015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/53\">",
"      Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012; 379:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/54\">",
"      Mofenson LM. Protecting the next generation--eliminating perinatal HIV-1 infection. N Engl J Med 2010; 362:2316.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/hiv/pub/mtct/antiretroviral/en/index.html (Accessed on September 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/56\">",
"      Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008; 49:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/57\">",
"      Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/58\">",
"      Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010; 54:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/59\">",
"      Chung MH, Kiarie JN, Richardson BA, et al. Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS 2005; 19:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/60\">",
"      Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/61\">",
"      Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/62\">",
"      Kesho Bora Study Group. Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial. Clin Infect Dis 2012; 55:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/63\">",
"      John-Stewart GC. When is replacement feeding safe for infants of HIV-infected women? PLoS Med 2007; 4:e30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/64\">",
"      Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/65\">",
"      Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999; 353:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/66\">",
"      Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/67\">",
"      Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, C&ocirc;te d'Ivoire: a randomised trial. Lancet 1999; 353:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/68\">",
"      Kuhn L, Reitz C, Abrams EJ. Breastfeeding and AIDS in the developing world. Curr Opin Pediatr 2009; 21:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/69\">",
"      Tonwe-Gold B, Ekouevi DK, Viho I, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 2007; 4:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/70\">",
"      Kafulafula G, Hoover DR, Taha TE, et al. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010; 53:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/71\">",
"      Onyango-Makumbi C, Bagenda D, Mwatha A, et al. Early Weaning of HIV-Exposed Uninfected Infants and Risk of Serious Gastroenteritis: Findings from Two Perinatal HIV Prevention Trials in Kampala, Uganda. J Acquir Immune Defic Syndr 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/72\">",
"      Arpadi S, Fawzy A, Aldrovandi GM, et al. Growth faltering due to breastfeeding cessation in uninfected children born to HIV-infected mothers in Zambia. Am J Clin Nutr 2009; 90:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/73\">",
"      Simondon KB. Early breast-feeding cessation and infant mortality in low-income countries: workshop summary. Adv Exp Med Biol 2009; 639:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/74\">",
"      Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 2008; 359:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/75\">",
"      Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/76\">",
"      Kuhn L, Sinkala M, Kankasa C, et al. High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission. PLoS One 2007; 2:e1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/77\">",
"      Iliff PJ, Piwoz EG, Tavengwa NV, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 2005; 19:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/78\">",
"      Becquet R, Bland R, Leroy V, et al. Duration, pattern of breastfeeding and postnatal transmission of HIV: pooled analysis of individual data from West and South African cohorts. PLoS One 2009; 4:e7397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/79\">",
"      Rollins NC, Filteau SM, Coutsoudis A, Tomkins AM. Feeding mode, intestinal permeability, and neopterin excretion: a longitudinal study in infants of HIV-infected South African women. J Acquir Immune Defic Syndr 2001; 28:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/80\">",
"      Coutsoudis A, Kuhn L, Pillay K, Coovadia HM. Exclusive breast-feeding and HIV transmission. AIDS 2002; 16:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/81\">",
"      Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/23/29050/abstract/82\">",
"      Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52:1069.",
"     </a>",
"    </li>",
"    <li>",
"     Lidstrom J, Guay L, Musoke P, et al. Multi-class drug resistance arises frequently in HIV-infected breastfeeding infants whose mothers initiate HAART postpartum. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 16-19, 2010 (Abs. 920).",
"    </li>",
"    <li>",
"     file://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf (Accessed on August 30, 2010).",
"    </li>",
"    <li>",
"     World Health Organization. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants, programmatic update. April 2012. file://whqlibdoc.who.int/hq/2012/WHO_HIV_2012.6_eng.pdf (Accessed on July 05, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13970 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29050=[""].join("\n");
var outline_f28_23_29050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H449464\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1758078\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1758085\">",
"      EPIDEMIOLOGY OF HIV TRANSMISSION THROUGH BREASTFEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1808791\">",
"      Risk of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76014255\">",
"      Estimating the risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76014262\">",
"      Biologic plausibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1808798\">",
"      Risk of replacement feeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1809716\">",
"      MECHANISM OF BREAST MILK HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1758092\">",
"      TIMING OF BREAST MILK HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1758099\">",
"      COFACTORS FOR BREAST MILK HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1758107\">",
"      Virologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1758114\">",
"      Immunologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1758121\">",
"      Breast infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4733392\">",
"      IMPORTANCE OF ANTIRETROVIRAL MEDICATIONS IN PREVENTING INFANT HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4733597\">",
"      Role of antiretroviral medications during antepartum, intrapartum and early postpartum period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4733676\">",
"      Role of antiretroviral medications during the breastfeeding period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1809829\">",
"      CLINICAL TRIALS OF ANTIRETROVIRAL DRUGS TO PREVENT HIV TRANSMISSION THROUGH BREASTFEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1809848\">",
"      Infant antiretroviral prophylaxis to prevent HIV acquisition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1809884\">",
"      Maternal antiretroviral drug use to prevent infant HIV transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1809914\">",
"      Maternal versus infant antiretroviral prophylaxis to reduce HIV transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1158900\">",
"      Lessons learned from clinical trial data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H84760941\">",
"      - Viral suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H84760948\">",
"      - Duration of postnatal antiretroviral regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H84760922\">",
"      - Timing of maternal antiretroviral prophylaxis for the prevention of HIV transmission during breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159929\">",
"      PHARMACOKINETICS OF ANTIRETROVIRAL MEDICATIONS DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64402186\">",
"      DRUG TOXICITY CONCERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2568674\">",
"      Fetal and infant toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2568681\">",
"      Risk of ART interruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13613012\">",
"      PREVENTION OF HIV TRANSMISSION THROUGH CHANGES IN INFANT FEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13613019\">",
"      Replacement feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13613026\">",
"      Shortened breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13613033\">",
"      Mixed feeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84761065\">",
"      ANTIRETROVIRAL DRUGS FOR THE PREVENTION OF PERINATAL HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449181\">",
"      STRATEGIES TO PREVENT INFANT HIV TRANSMISSION DURING BREASTFEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13613247\">",
"      WHO guidelines for infant feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13613306\">",
"      Choice of antiretroviral strategy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15492367\">",
"      - Women who meet HIV treatment criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15492385\">",
"      - Women who do not meet HIV treatment criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H64402577\">",
"      Option A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H64402601\">",
"      Option B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H215891148\">",
"      Option B plus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1158931\">",
"      - Women who present late or during labor for care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84760969\">",
"      Dosing of antiretroviral medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H449464\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13970\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13970|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/6/17517\" title=\"table 1\">",
"      WHO clinical staging HIV criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/22/36203\" title=\"table 2\">",
"      ART recommendations for eligible HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/29/37340\" title=\"table 3\">",
"      ARV prophylaxis for women not needing treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/35/41531\" title=\"table 4\">",
"      Infant NVP dosing recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/16/11531\" title=\"table 5\">",
"      Infant AZT dosing recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10794?source=related_link\">",
"      Adverse effects of antiretroviral therapy in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16328?source=related_link\">",
"      Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=related_link\">",
"      Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=related_link\">",
"      Antiretroviral medications in pregnancy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=related_link\">",
"      Structured treatment interruptions in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_23_29051="Coping with menopause PI";
var content_f28_23_29051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ways to cope with menopause symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        What you can do",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Hot flashes and night sweats",
"       </td>",
"       <td>",
"        Dress in layers so you can take off clothes if you get hot.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep the thermostat down and avoid hot drinks, like coffee or tea.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Put a cold, wet washcloth against your neck during hot flashes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quit smoking, if you smoke. (Smoking makes hot flashes worse.)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Vaginal dryness",
"       </td>",
"       <td>",
"        Use lubricants before sex.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use a vaginal moisturizer, such as Replens&reg; or Lubrin&reg;.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep in mind that having sex or masturbating can help keep the vagina healthy.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Sleep problems",
"       </td>",
"       <td>",
"        Go to sleep and get up at the same time every day, even when you don't sleep well. (Taking naps can make the problem worse.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid caffeine in the afternoon and don't drink much alcohol.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Depression",
"       </td>",
"       <td class=\"divider_top\">",
"        Try to stay active. Exercise helps ward off depression.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seek social support from women like you.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29051=[""].join("\n");
var outline_f28_23_29051=null;
var title_f28_23_29052="Dietary sources of zinc";
var content_f28_23_29052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zinc content of selected foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amount",
"       </td>",
"       <td class=\"subtitle1\">",
"        Zinc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Oysters",
"       </td>",
"       <td>",
"        6 medium",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        80 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        84 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Liver",
"       </td>",
"       <td>",
"        3.5 oz",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        6.1 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Hamburger",
"       </td>",
"       <td>",
"        3.5 oz",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        4.9 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cheerios",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        3.7 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22.4 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Sunflower seeds",
"       </td>",
"       <td>",
"        1 oz",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        1.6 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Pecans",
"       </td>",
"       <td>",
"        1 oz",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        1.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Chicken (white meat)",
"       </td>",
"       <td>",
"        3.5 oz",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        1.0 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Milk (whole, skim)",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        0.9 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        240 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Brown rice",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        0.6 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        97 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Egg (1 whole)",
"       </td>",
"       <td>",
"        1 large",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        0.5 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        White rice",
"       </td>",
"       <td>",
"        2/3 cup&nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        0.4 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        124 g",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29052=[""].join("\n");
var outline_f28_23_29052=null;
var title_f28_23_29053="Drugs interact theophylline II";
var content_f28_23_29053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinically significant drug interactions with theophylline",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of interaction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on theophylline serum",
"concentrations or pharmacologic effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon, human recombinant alpha-A",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        100 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoproterenol (IV)",
"       </td>",
"       <td>",
"        Increases theophylline clearance",
"       </td>",
"       <td>",
"        20 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketamine",
"       </td>",
"       <td>",
"        Pharmacologic",
"       </td>",
"       <td>",
"        May lower theophylline seizure threshold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithium",
"       </td>",
"       <td>",
"        Theophylline increases lithium renal clearance",
"       </td>",
"       <td>",
"        Lithium dose required to achieve a therapeutic serum",
"concentration increased an average of 60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lorazepam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate (MTX)",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        20 percent increase after low-dose MTX, higher dose MTX",
"may have a greater effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mexiletine",
"       </td>",
"       <td>",
"        Similar to disulfiram",
"       </td>",
"       <td>",
"        80 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midazolam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"       <td>",
"        Similar to diazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moricizine",
"       </td>",
"       <td>",
"        Increases theophylline clearance",
"       </td>",
"       <td>",
"        25 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancuronium",
"       </td>",
"       <td>",
"        Theophylline may antagonize non-depolarizing",
"neuromuscular blocking effects; possibly due to phosphodiesterase",
"inhibition",
"       </td>",
"       <td>",
"        Larger dose of pancuronium may be required to achieve",
"neuromuscular blockade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentoxifylline",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        30 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenobarbital (PB)",
"       </td>",
"       <td>",
"        Similar to aminoglutethimide",
"       </td>",
"       <td>",
"        25 percent decrease after more than two weeks of",
"concurrent PB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Phenytoin",
"       </td>",
"       <td>",
"        Phenytoin increases theophylline clearance by",
"increasing microsomal enzyme activity",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Serum theophylline and phenytoin concentrations",
"decrease about 40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theophylline decreases phenytoin absorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propafenone",
"       </td>",
"       <td>",
"        Decreases theophylline clearance and pharmacologic",
"interaction",
"       </td>",
"       <td>",
"        40 percent increase. Beta-2-blocking effect may",
"decrease efficacy of theophylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propranolol",
"       </td>",
"       <td>",
"        Similar to cimetidine and pharmacologic interaction",
"       </td>",
"       <td>",
"        100 percent increase. Beta-2-blocking effect may",
"decrease efficacy of theophylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"       <td>",
"        Increases theophylline clearance by increasing",
"cytochrome P450 1A2 and 3A3 activity",
"       </td>",
"       <td>",
"        20 to 40 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfinpyrazone",
"       </td>",
"       <td>",
"        Increases theophylline clearance by increasing",
"demethylation and hydroxylation. Decreases renal clearance of",
"theophylline",
"       </td>",
"       <td>",
"        20 percent decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tacrine",
"       </td>",
"       <td>",
"        Similar to cimetidine, also increases renal clearance",
"of theophylline",
"       </td>",
"       <td>",
"        90 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiabendazole",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        190 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ticlopidine",
"       </td>",
"       <td>",
"        Decreases theophylline clearance",
"       </td>",
"       <td>",
"        60 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Troleandomycin",
"       </td>",
"       <td>",
"        Similar to erythromycin",
"       </td>",
"       <td>",
"        33 to 100 percent increase depending on troleandomycin",
"dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verapamil",
"       </td>",
"       <td>",
"        Similar to disulfiram",
"       </td>",
"       <td>",
"        20 percent increase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zafirlukast",
"       </td>",
"       <td>",
"        Mechanism not studied; theophylline decreases either",
"bioavailability or",
"clearance of zafirlukast. Zafirlukast has no effect on theophylline",
"clearance",
"       </td>",
"       <td>",
"        Zafirlukast blood levels decrease an average of 40",
"percent, which is likely to render it ineffective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zileuton",
"       </td>",
"       <td>",
"        Zileuton inhibits cytochrome P-450 1A2 and, thus,",
"decreases theophylline clearance",
"       </td>",
"       <td>",
"        100 percent increase",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Hendeles, L, Jenkins, J, Temple, R, Pharmacotherapy 1995; 15:409.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29053=[""].join("\n");
var outline_f28_23_29053=null;
var title_f28_23_29054="Contents: Urogynecology";
var content_f28_23_29054=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Urogynecology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Urogynecology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Pelvic relaxation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/33/40473\">",
"           An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/47/4857\">",
"           Clinical manifestations, diagnosis, and nonsurgical management of posterior vaginal defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34263\">",
"           Delayed surgical management of the disrupted anal sphincter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/56/9097\">",
"           Fecal incontinence related to pregnancy and vaginal delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25976\">",
"           Laparoscopic surgery for repair of pelvic floor defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/62/26602\">",
"           Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/18/19753\">",
"           Pelvic floor disorders associated with pregnancy and childbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/32/1546\">",
"           Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/7/9337\">",
"           Pelvic organ prolapse in women: Choosing a primary surgical procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/46/8937\">",
"           Pelvic organ prolapse in women: Diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/37/43607\">",
"           Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/8/7306\">",
"           Pelvic organ prolapse in women: Surgical repair of anterior vaginal wall prolapse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/4/35914\">",
"           Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/33/11799\">",
"           Reconstructive materials used in surgery: Classification and host response",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/24/44424\">",
"           Surgical management of posterior vaginal defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17530\">",
"           Vaginal pessary treatment of prolapse and incontinence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/14/29929\">",
"           Clinical presentation and diagnosis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/57/29592\">",
"           Diagnostic cystourethroscopy for gynecologic conditions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/1/7192\">",
"           Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/22/43369\">",
"           Management of interstitial cystitis/bladder pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/8/8330\">",
"           Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/32/1546\">",
"           Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32951\">",
"           Rectovaginal, anovaginal, and colovesical fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43177\">",
"           Stress urinary incontinence in women: Choosing a primary surgical procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/43/16055\">",
"           Stress urinary incontinence in women: Choosing a type of midurethral sling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/23/44409\">",
"           Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/58/17319\">",
"           Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/49/33562\">",
"           Stress urinary incontinence in women: Retropubic midurethral slings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33401\">",
"           Stress urinary incontinence in women: Transobturator midurethral slings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/4/32842\">",
"           Treatment of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/15/26873\">",
"           Urethral diverticulum in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/23/32120\">",
"           Urodynamic evaluation of women with incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/47/44792\">",
"           Urogenital tract fistulas in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19336\">",
"           Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-1F6D213DE4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_23_29054=[""].join("\n");
var outline_f28_23_29054=null;
var title_f28_23_29055="Nasal CPAP masks";
var content_f28_23_29055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal CPAP masks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Standard nasal masks used for noninvasive positive pressure ventilation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_23_29055=[""].join("\n");
var outline_f28_23_29055=null;
